Wie Novartis auf dem Markt für Medikamente zur Gewichtsabnahme erfolgreich sein will, ohne direkt mit Eli Lilly zu konkurrieren
Während Behandlungen zur Gewichtsabnahme den Pharmamarkt dominieren, wählt der Schweizer Arzneimittelhersteller Novartis AG ...
fuw.ch25d
Novartis Pharma schliesst Abkommen mit Lindy Biosciences
Die Novartis-Tochter Novartis Pharma hat ein Lizenz- und Kooperationsabkommen mit der US-Biotechnologiefirma Lindy Biosciences geschlossen. Im Rahmen der Zusammenarbeit sollen ausgewählte Medikamente ...
STAT4d
FDA awards Novartis expanded approval for breast cancer therapy
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...
Investopedia6d
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Milan Jaros / Bloomberg via Getty Images Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease. The drug maker reported Kisqali along ...
Reuters29d
Novartis receives binding offer from Siemens Healthineers for molecular imaging business
Aug 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab said on Saturday it had received a binding offer from Germany's Siemens Healthineers (SHLG.DE), opens new tab to acquire its ...
pharmaphorum25d
Novartis builds case for Leqvio with monotherapy data
Novartis has a long way to go to make its twice-yearly cholesterol-lowering drug Leqvio the multi-billion-dollar blockbuster it is predicting – but took another step along that road today.
FiercePharma25d
With phase 3 win, Novartis pads case for broader use of heart med Leqvio
Three years after launching Leqvio in the U.S., Novartis is still steadily advancing its blockbuster ambitions for the cholesterol-lowering drug. Early Wednesday, the company touted phase 3 ...
Bloomberg L.P.6d
Novartis Breast Cancer Drug Helped Delay Return of Disease
Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that will be closely compared with a rival product from Eli Lilly. Novartis ...
Yahoo Finance1mon
Novartis and Versant launch Borealis Biosciences with $150m
Novartis has partnered with Versant Ventures to establish Borealis Biosciences, a Canada-based independent, discovery-stage biotech company. The collaboration has resulted in $150m Series A ...
FiercePharma20d
Novartis brings blood cancer sculptures to Scotland, continuing symptom awareness tour
Novartis’ blood cancer sculpture tour has reached a new destination. The Swiss drugmaker, which put the sculptures on show in London one year ago, is marking this year’s Blood Cancer Awareness ...
The Globe and Mail29d
Novartis receives binding offer from Siemens Healthineers for molecular imaging business
Swiss drugmaker Novartis said on Saturday it had received a binding offer from Germany’s Siemens Healthineers to acquire its molecular imaging business for Fluorine-18 positron emission ...